JP5820819B2 - カロリー制限の模倣に有効な食餌療法 - Google Patents
カロリー制限の模倣に有効な食餌療法 Download PDFInfo
- Publication number
- JP5820819B2 JP5820819B2 JP2012548051A JP2012548051A JP5820819B2 JP 5820819 B2 JP5820819 B2 JP 5820819B2 JP 2012548051 A JP2012548051 A JP 2012548051A JP 2012548051 A JP2012548051 A JP 2012548051A JP 5820819 B2 JP5820819 B2 JP 5820819B2
- Authority
- JP
- Japan
- Prior art keywords
- animal
- diet
- caloric restriction
- amount
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000005911 diet Nutrition 0.000 title claims description 157
- 238000002560 therapeutic procedure Methods 0.000 title claims description 16
- 230000000378 dietary effect Effects 0.000 title claims description 6
- 235000020827 calorie restriction Nutrition 0.000 title description 6
- 241001465754 Metazoa Species 0.000 claims description 188
- 230000037213 diet Effects 0.000 claims description 150
- 235000020934 caloric restriction Nutrition 0.000 claims description 97
- 235000015872 dietary supplement Nutrition 0.000 claims description 95
- 230000003278 mimic effect Effects 0.000 claims description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 26
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 20
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 14
- 230000000366 juvenile effect Effects 0.000 claims description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 13
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 13
- 229930003268 Vitamin C Natural products 0.000 claims description 13
- 229930003427 Vitamin E Natural products 0.000 claims description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 13
- 235000019154 vitamin C Nutrition 0.000 claims description 13
- 239000011718 vitamin C Substances 0.000 claims description 13
- 235000019165 vitamin E Nutrition 0.000 claims description 13
- 229940046009 vitamin E Drugs 0.000 claims description 13
- 239000011709 vitamin E Substances 0.000 claims description 13
- 241000218628 Ginkgo Species 0.000 claims description 12
- 235000011201 Ginkgo Nutrition 0.000 claims description 12
- 239000009140 Grape Seed Proanthocyanidin Substances 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 12
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims description 4
- HSNZZMHEPUFJNZ-QMTIVRBISA-N D-keto-manno-heptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-QMTIVRBISA-N 0.000 claims description 3
- VRYALKFFQXWPIH-RANCGNPWSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxy-2-tritiohexanal Chemical compound O=CC([3H])[C@@H](O)[C@H](O)[C@H](O)CO VRYALKFFQXWPIH-RANCGNPWSA-N 0.000 claims description 2
- 241000282414 Homo sapiens Species 0.000 claims description 2
- 102000016267 Leptin Human genes 0.000 claims description 2
- 108010092277 Leptin Proteins 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 2
- 229940039781 leptin Drugs 0.000 claims description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 239000002207 metabolite Substances 0.000 description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 230000002503 metabolic effect Effects 0.000 description 8
- WHBMMWSBFZVSSR-GSVOUGTGSA-N (R)-3-hydroxybutyric acid Chemical compound C[C@@H](O)CC(O)=O WHBMMWSBFZVSSR-GSVOUGTGSA-N 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 241000282326 Felis catus Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000021196 dietary intervention Nutrition 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 238000000513 principal component analysis Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 235000007882 dietary composition Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004066 metabolic change Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 3
- 239000000123 paper Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 3
- 229940076788 pyruvate Drugs 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920001991 Proanthocyanidin Polymers 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 235000004251 balanced diet Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000020940 control diet Nutrition 0.000 description 2
- 238000002790 cross-validation Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000021004 dietary regimen Nutrition 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000001890 gluconeogenic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- -1 method Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 241000282421 Canidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940090568 combinations of vitamin Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 229940098326 grape seed proanthocyanidins Drugs 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 235000014705 isoleucine Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000647 material safety data sheet Toxicity 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000002374 tyrosine Nutrition 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33544810P | 2010-01-06 | 2010-01-06 | |
| US61/335,448 | 2010-01-06 | ||
| PCT/US2011/000020 WO2011084886A1 (en) | 2010-01-06 | 2011-01-05 | Dietary regimens useful for mimicking caloric restriction |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013516188A JP2013516188A (ja) | 2013-05-13 |
| JP2013516188A5 JP2013516188A5 (enExample) | 2014-02-13 |
| JP5820819B2 true JP5820819B2 (ja) | 2015-11-24 |
Family
ID=44305756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548051A Expired - Fee Related JP5820819B2 (ja) | 2010-01-06 | 2011-01-05 | カロリー制限の模倣に有効な食餌療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20120301559A1 (enExample) |
| EP (1) | EP2521460A4 (enExample) |
| JP (1) | JP5820819B2 (enExample) |
| CN (1) | CN102695428A (enExample) |
| AU (1) | AU2011203800A1 (enExample) |
| BR (1) | BR112012016560A2 (enExample) |
| CA (1) | CA2785997A1 (enExample) |
| MX (1) | MX340938B (enExample) |
| RU (1) | RU2558540C2 (enExample) |
| WO (1) | WO2011084886A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130316029A1 (en) * | 2010-12-21 | 2013-11-28 | Nestec S.A. | Methods and compositions suitable for managing blood glucose in animals |
| MX2014000419A (es) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
| BR112015010947A2 (en) | 2012-11-13 | 2018-06-05 | Nusirt Sciences, Inc. | compositions and methods for increasing energy metabolism. |
| SG11201507046UA (en) | 2013-03-15 | 2015-10-29 | Nusirt Sciences Inc | Leucine and nicotinic acid reduces lipid levels |
| AU2014238377A1 (en) * | 2013-03-15 | 2015-09-10 | Nusirt Sciences, Inc. | Treatment of pets with sirtuin activators |
| CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
| CN120436205A (zh) | 2015-02-13 | 2025-08-08 | 马斯公司 | 包装宠物食物产品 |
| EP3291693A4 (en) | 2015-05-06 | 2019-04-03 | University of Southern California | FASTENIMITIER AND IMPROVING DIET FOR THE TREATMENT OF HYPERTENSION AND LIPID DISORDER |
| GB201522304D0 (en) | 2015-12-17 | 2016-02-03 | Mars Inc | Food product for reducing muscle breakdown |
| JP2020501502A (ja) * | 2016-12-15 | 2020-01-23 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | コンパニオンアニマルにおける消化率を調節する組成物及び方法 |
| US11284640B2 (en) | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| CA3073827C (en) * | 2017-09-07 | 2023-10-17 | Liposcience, Inc. | Multi-parameter metabolic vulnerability index evaluations |
| GB201721627D0 (en) | 2017-12-21 | 2018-02-07 | Mars Inc | Pet food product |
| JP7865738B2 (ja) * | 2018-11-09 | 2026-05-26 | エル－ニュートラ・インコーポレイテッド | 断続的断食模倣のための栄養バー |
| WO2020121336A1 (en) * | 2018-12-14 | 2020-06-18 | National Institute Of Immunology | A method of mimicking benefits of dietary restriction by transiently upregulating er stress response |
| IT202000007726A1 (it) | 2020-04-10 | 2021-10-10 | Solongevity Nutraceuticals S R L | Composizioni mimetiche della restrizione calorica |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060116330A1 (en) * | 1997-07-08 | 2006-06-01 | The Iams Company | Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose |
| EP1250052A1 (en) * | 2000-01-25 | 2002-10-23 | Juvenon, Inc. | Nutritional supplements for aged pets |
| US20030060503A1 (en) * | 2000-01-25 | 2003-03-27 | Juvenon, Inc. | Nutritional supplements for mature pets |
| US20020076470A1 (en) * | 2000-10-31 | 2002-06-20 | Colgate-Palmolive Company | Composition and method |
| US20020115710A1 (en) * | 2000-10-31 | 2002-08-22 | Zicker Steven Curtis | Composition and method |
| BR0207948A (pt) * | 2001-03-09 | 2004-07-27 | Produits Nestel S A Soc D | Composição que melhora os déficits fisiológicos relacionados com a idade e que aumenta a longevidade |
| US7666459B2 (en) * | 2001-09-12 | 2010-02-23 | The Procter & Gamble Company | Pet food compositions |
| KR20050042495A (ko) * | 2002-09-09 | 2005-05-09 | 네스텍소시에테아노님 | 모발 및 외피 성질을 개선시키기 위한 경구적으로 투여가능한 조성물 |
| WO2005006878A1 (en) * | 2003-07-07 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions for improved oxidative status in companion animals |
| CN1308007C (zh) * | 2003-08-26 | 2007-04-04 | 贲晓明 | 大脑营养增强物质 |
| WO2006053010A2 (en) * | 2004-11-09 | 2006-05-18 | Hill's Pet Nutrition, Inc. | Use of antioxidants for gene modulation |
| US8168161B2 (en) * | 2004-12-22 | 2012-05-01 | Hill's Pet Nutrition, Inc. | Method to promote oral health in companion animals |
| BRPI0519642A8 (pt) * | 2004-12-29 | 2017-10-03 | Hill´S Pet Nutrition Inc | Método para inibir um declínio em aprendizagem e/ou memória, kit apropriado para administrar um ou mais antioxidantes a um animal, meio para transmitir informação, e, uso de uma composição |
| BRPI0613000A2 (pt) * | 2005-07-14 | 2012-12-04 | Hills Pet Nutrition Inc | método para aumentar a longevidade de um animal, artigo de fabricação, kit, e, meio de comunicação de informação acerca de ou instruções para a administração a um animal velho de uma composição |
| AU2007204692B2 (en) * | 2006-01-10 | 2011-06-02 | Hill's Pet Nutrition, Inc. | Compositions and method for promoting fat loss |
| WO2007088046A2 (en) * | 2006-02-01 | 2007-08-09 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| US8242100B2 (en) * | 2006-02-28 | 2012-08-14 | Nestec Sa | Compositions and methods for inducing bone growth and inhibiting bone loss |
| US8012513B2 (en) * | 2006-06-08 | 2011-09-06 | The Procter & Gamble Company | Method for promoting eye health |
-
2011
- 2011-01-05 CA CA2785997A patent/CA2785997A1/en not_active Abandoned
- 2011-01-05 WO PCT/US2011/000020 patent/WO2011084886A1/en not_active Ceased
- 2011-01-05 MX MX2012007810A patent/MX340938B/es active IP Right Grant
- 2011-01-05 JP JP2012548051A patent/JP5820819B2/ja not_active Expired - Fee Related
- 2011-01-05 BR BRBR112012016560-7A patent/BR112012016560A2/pt not_active IP Right Cessation
- 2011-01-05 CN CN2011800055437A patent/CN102695428A/zh active Pending
- 2011-01-05 RU RU2012133461/13A patent/RU2558540C2/ru not_active IP Right Cessation
- 2011-01-05 US US13/519,224 patent/US20120301559A1/en not_active Abandoned
- 2011-01-05 AU AU2011203800A patent/AU2011203800A1/en not_active Abandoned
- 2011-01-05 EP EP11732006.9A patent/EP2521460A4/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013516188A (ja) | 2013-05-13 |
| CN102695428A (zh) | 2012-09-26 |
| EP2521460A4 (en) | 2013-06-26 |
| RU2012133461A (ru) | 2014-02-20 |
| CA2785997A1 (en) | 2011-07-14 |
| WO2011084886A1 (en) | 2011-07-14 |
| MX2012007810A (es) | 2012-09-21 |
| RU2558540C2 (ru) | 2015-08-10 |
| US20120301559A1 (en) | 2012-11-29 |
| AU2011203800A1 (en) | 2012-07-19 |
| MX340938B (es) | 2016-08-01 |
| BR112012016560A2 (pt) | 2015-09-01 |
| EP2521460A1 (en) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013516188A (ja) | カロリー制限の模倣に有効な食餌療法 | |
| EP3058942B1 (en) | Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing cognitive and related functions | |
| AU2009210728B2 (en) | Compositions and methods for influencing recovery from strenuous physical activity | |
| JP5537809B2 (ja) | 脳機能を維持するための組成物及び方法 | |
| RU2558534C2 (ru) | Способы предупреждения или лечения саркопении и мышечной атрофии у животных | |
| AU2016281870B2 (en) | Compositions and methods for enhancing neurogenesis in animals | |
| JP5863656B2 (ja) | 動物の認知機能及び認知関連機能を向上させるための組成物及び方法 | |
| CN101820754A (zh) | 用于增强认知功能的组合物与方法 | |
| CN101132700B (zh) | 用以改善肾功能的组合物和方法 | |
| US20130316029A1 (en) | Methods and compositions suitable for managing blood glucose in animals | |
| AU2006299665B2 (en) | Methods and compositions for improving cognitive function | |
| JP2020532960A (ja) | 長期的なカロリー制限を再現し、動物に健康上の利益を与えるための方法 | |
| Moyers | Canine nutrition for a healthy old age | |
| BR112020002872B1 (pt) | Kit adequado para simular restrição calórica crônica para transmitir um benefício à saúde em um animal e/ou para alimentar um animal para transmitir um benefício à saúde do animal, e uso de dietas para simular restrição calórica crônica | |
| BR112020003288B1 (pt) | Kit adequado para um procedimento de dieta para alimentar um animal para transmitir um benefício à saúde do animal por meio de dieta de restrição calórica intermitente, e uso de diétas para alimentar um animal para conferir um benefício de saúde | |
| US20160015057A1 (en) | Nutritional supplement/feed formula and methods of use thereof to reduce development of osteochondrosis dissecans (ocd) lesions | |
| BR112017010381B1 (pt) | Uso de triglicerídeos de cadeia média para preparação de uma composição alimentícia para acentuar o efeito de fármaco antiepiléptico notratamento de epilepsia em um animal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131219 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131219 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140916 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141028 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150126 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150908 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151005 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5820819 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |